The compound Tert-Butyl(2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(Methoxycarbonyl)-l-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate functions as the penultimate advanced intermediate in the convergent assembly of the hepatitis C virus NS5A inhibitor ledipasvir (CAS 1256388-51-8). With a monoisotopic mass approaching 881 Da and a stoichiometric formula that embeds four discrete stereocenters, the material exists as a single, defined isomer whose optical purity directly governs the diastereomeric integrity of the downstream active pharmaceutical ingredient. Industrially, the substance is isolated as an off-white to pale yellow amorphous powder following silica gel chromatography of the palladium-catalyzed Suzuki–Miyaura coupling that joins the boronate-bearing imidazole–pyrrolidine fragment to the halogenated polycyclic core. Because the molecule bears a methoxycarbonyl-l-valine cap on one pyrrolidine terminus while retaining an acid-labile tert-butoxycarbonyl (Boc) protecting group on the opposite methoxymethyl-substituted pyrrolidine, it straddles the boundary between a fully protected precursor and the final salt-free API, serving as the last stable intermediate before global deprotection.
When does this intermediate require refrigerated storage? Stability data generated under ICH Q1A(R2) conditions indicate that the Boc carbamate undergoes observable thermal deprotection when stored above 8 °C for periods exceeding 72 h, with the des-Boc impurity reaching the 0.10% threshold at 25 °C/60% RH within one week. Consequently, long-term storage is maintained at −20 ± 5 °C in sealed, argon-purged high-density polyethylene drums equipped with desiccant cartridges. Re-test dating is set at 24 months from the date of manufacture, with a container-closure integrity requirement verified via helium leak testing per ASTM F2392. For bulk shipments of 1–5 kg, validated cold-chain logistics employing phase-change materials and real-time temperature data loggers are mandated; excursions beyond 0 °C for more than 8 cumulative hours trigger out-of-specification investigation in accordance with 21 CFR 211.192.
Chromatographic Identity Panel and Enantiomeric Excess Control
A reversed-phase HPLC method using a C18 column (150 × 4.6 mm, 3 µm particle size) with a gradient of 0.1% trifluoroacetic acid in water and acetonitrile delivers retention of the target compound at 12.8 min. System suitability requirements mandate resolution ≥2.0 between the product and its des-Boc analogue, and the reporting threshold is set at 0.05% in compliance with ICH Q3A(R2) for unspecified impurities. A chiral stationary-phase assay (amylose tris(3,5-dimethylphenylcarbamate) coated on 5 µm silica, 250 × 4.6 mm, n-hexane/ethanol/0.1% diethylamine) resolves the four possible diastereomers arising from epimerization at the 2- and 4- positions of the methoxymethylpyrrolidine moiety. Routine release specifications require an enantiomeric excess ≥99.4% for the desired (2S,4S) configuration; the (2R,4S) epimer, which has been identified as a process-specific impurity formed during the coupling reaction, is controlled at ≤0.30%. Palladium content is determined by inductively coupled plasma mass spectrometry following microwave-assisted acid digestion and is limited to ≤10 ppm, aligning with the ICH Q3D oral permitted daily exposure for elemental impurities in drug substances.
How does the mono-Boc intermediate improve upon a symmetrical bis-Boc route?
Earlier-generation synthetic schemes employed a fully Boc-protected dimeric precursor that required simultaneous global deprotection of two carbamate moieties, invariably generating a mixture of mono-Boc, fully deprotected, and dimeric byproducts that complicated purification. By advancing a single-cap intermediate, the manufacturer gains orthogonal reactivity: the methoxycarbonylvaline terminus is unreactive under the mildly acidic conditions (4 M HCl in 1,4-dioxane, 0–5 °C) employed to remove the Boc group, while the free amine liberated on the opposite pyrrolidine enables direct salt formation with phosphoric acid to yield the dihydrogenphosphate monohydrate API crystal form. Process analytical technology data from pilot-plant campaigns indicate that the isolated yield of ledipasvir phosphate is increased by 12–15% relative to the bis-Boc approach, with dimeric impurity levels held below 0.15% throughout the deprotection. The table below contrasts the critical quality attributes of the monoprotected intermediate with those of a bis-Boc analog that remains a common commercial offering.
| Attribute | Monoprotected intermediate (this product) | Bis-Boc dimeric precursor |
|---|---|---|
| Protecting group configuration | Single Boc on methoxymethylpyrrolidine; valine cap pre-installed | Two Boc groups; no valine cap |
| Typical HPLC purity (area %) | ≥98.5 | ≥97.0 |
| Key process-related impurity | Des-Boc species; (2R,4S)-epimer | Mono-deprotected species; homodimer |
| Subsequent transformation | Single deprotection → salt formation → API | Dual deprotection, cap introduction, then salt formation |
| Solubility in tetrahydrofuran at 25 °C | >50 mg/mL | 30–40 mg/mL |
| Storage condition | −20 °C, desiccated | 2–8 °C, desiccated |
The deprotection step that converts the monoprotected intermediate into ledipasvir freebase is exquisitely sensitive to thermal overshoot. Reaction calorimetry performed in a 100 L glass-lined reactor (HCl/dioxane, 2.5 equivalents, addition over 30 min) reveals that the temperature must be maintained within the window 0–5 °C. If the jacket temperature control loop allows the batch to exceed 8 °C for more than 15 min, epimerization at the methoxymethyl-bearing stereocenter accelerates sharply, with the (2R,4S)-epimer reaching 1.2% within 45 min—a concentration that cannot be purged by recrystallization of the final phosphate salt. To mitigate this risk, commercial campaigns employ a cascade control strategy with a sub-ambient secondary coolant loop and in situ FTIR monitoring of the Boc carbonyl stretching frequency at 1695 cm−1; the endpoint is declared when the signal decays to ≤2% of its initial intensity, typically after 2.5–3.0 h. Following aqueous work-up, the resulting freebase is extracted into ethyl acetate, washed with 10% w/w sodium bicarbonate to remove residual HCl, and concentrated below 30 °C under reduced pressure to avoid thermal deglycation.
Residual solvent control is governed by USP <467> and ICH Q3C, with headspace gas chromatography confirming that dichloromethane (used in the penultimate coupling) does not exceed 600 ppm, acetonitrile 410 ppm, and N,N-dimethylformamide 880 ppm. Any batch presenting N,N-dimethylacetamide above 1090 ppm is subject to re-slurry in 2-propanol/water (90:10 v/v) until the solvent level drops into the approved range. Palladium scavenging is performed with a macroporous polystyrene-bound trimercaptotriazine resin (0.5 wt% relative to the intermediate) in the crude reaction stream prior to isolation; ICP-MS analysis of production lots confirms Pd ≤7 ppm in over 95% of batches.
Granular impurity fate mapping across the deprotection cascade
A systematic forced-degradation study carried out under ICH Q1B photostability conditions (Option 1, 1.2 million lux·h visible, 200 Wh/m2 near-UV) establishes that the primary photodegradant is the oxidized imidazole-2-carboxaldehyde derivative, generated via singlet oxygen-mediated ring opening. This species, present at 0.07% in unexposed controls, escalates to 0.45% after 24 h of continuous UV exposure. Manufacturing suites handling the intermediate therefore employ sodium-vapor lighting and amber borosilicate glassware for all unit operations downstream of the Suzuki coupling. Additionally, process mass spectrometry identifies the des-Boc impurity (M+H⁺ 781.4) as the dominant thermal degradation product, and its formation is effectively suppressed by maintaining the moisture content of the dry powder below 0.3% w/w (Karl Fischer titration per USP <921>, Method Ia). During charging of the intermediate to the deprotection reactor, an inerted glovebox with a dew point ≤–50 °C is used, and the reactor is vacuum-nitrogen inerted in three cycles before solvent introduction.
For medicinal chemistry and process development groups, the intermediate is supplied in gram to kilogram quantities with an accompanying analytical dossier that includes a ¹H NMR spectrum (acquisition at 600 MHz, DMSO-d6), high-resolution mass spectrum (Q-TOF, ESI⁺), chiral HPLC chromatogram, residual palladium report, and a comprehensive listing of impurities observed above the 0.05% reporting threshold. The material is classified as a non-hazardous chemical substance under REACH and is shipped with a safety data sheet aligned to Regulation (EC) No 1907/2006; its transport hazard class is not assigned, permitting ambient cold-chain ground freight without ADR restrictions.
